Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib plus topical corticosteroids for moderate-to-severe atopic dermatitis after cyclosporine failure or intolerance
2017-004574-34Phase 3Unknown
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in atopic dermatitis (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Proportion of patients achieving Investigator's Global Assessment of 0 or 1 with at least 2-point improvement. Status: unknown.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2017-004574-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004574-34.